Tag archief: English Only

IFF to Present at CAGNY Conference February 18

NEW YORK–(BUSINESS WIRE)– Regulatory News: IFF (NYSE:IFF) (Euronext Paris: IFF) (TASE: IFF), a leading innovator of taste, scent and nutrition announced that the Company’s management will...

Nike Extends its Athletic Leadership

Expands record-breaking running platform and elevates the urgency of climate action BEAVERTON, Ore.–(BUSINESS WIRE)– Today, NIKE, Inc. (NYSE: NKE), unveiled breakthrough innovation for athletes competing...

Takeda Demonstrates Ongoing Commitment in Rare Hematology By Continuing to Gather Real-World Evidence and Advance Personalized Treatment

Takeda continues to gather and apply real-world evidence to improve the diagnosis of hemophilia and advance personalized treatment in its ongoing commitment to ensuring people...

ABB: Full-Year and Q4 2019 Results

Transformation on track FULL-YEAR 2019 HIGHLIGHTS Orders $28.6 billion, steady; comparable +1% Revenues $28.0 billion, +1%; comparable +1% Operational EBITA margin1 11.1%, impacted by a...

Samsung to Advance High Performance Computing Systems with Launch of Industry’s First 3rd-generation (16GB) HBM2E

New HBM2E stacks eight 16Gb DRAM dies to achieve 16GB package capacity and ensures a stable data transfer speed at 3.2Gbps SEOUL, South Korea–(BUSINESS WIRE)–...

1st AI-driven proactive suspension system for domain names

BRUSSELS–(BUSINESS WIRE)– Over 3.6 million .eu domain names are registered by businesses and private individuals. EURid, the organization that manages the .eu internet space, has...

 Rebiotix, a Ferring Company, Completes Enrollment for First-Ever, Pivotal Phase 3 Clinical Trial of Microbiota-based RBX2660

 Enrollment completion for the first Phase 3 clinical trial in microbiome industry Largest randomized, double-blinded study, with over 300 patients enrolled aimed to demonstrate the...

Boehringer Ingelheim receives approval for Aservo® EquiHaler®, industry first therapy for severe equine asthma

Aservo® EquiHaler® (ciclesonide inhalation solution) is a result of synergies between the company’s human pharma and animal health businesses. The inhaler addresses an unmet need...

Philip Morris International Recognized by CDP as a Global Leader in Sustainable Action

Leading International Nonprofit Places PMI on Its Water Security A List and Supplier Engagement Leaderboard, and Accords the Company an A- for Forest LAUSANNE, Switzerland–(BUSINESS...

ING Research: Customers Willing to Drop Brands Based on Perceived Environmental Impact

Survey finds consumer adoption of circular practices hinges on convenience, availability and understanding of sustainable options offered by companies NEW YORK & LONDON & SINGAPORE–(BUSINESS...

Expanded Partnership with SES to Give Princess Cruises First Access to Ground-Breaking O3b mPOWER Satellite-Based Communications System

Princess Cruises to host a series of events in 2020 to demonstrate elite global connectivity LUXEMBOURG & SANTA CLARITA, Calif.–(BUSINESS WIRE)– Princess Cruises, a leading...

Clovis Oncology Announces Availability and Reimbursement for Rubraca® (rucaparib) Tablets for Women with Relapsed Ovarian Cancer in France

Rubraca® (rucaparib) offers a new monotherapy maintenance treatment option for eligible women with relapsed, platinum-sensitive ovarian cancer, who harbor either a BRCA1/2 mutation or are...

CHMP issues positive opinions for both bempedoic acid and the bempedoic acid / ezetimibe fixed dose combination tablet as treatments for hypercholesterolaemia

Bempedoic acid is an oral, once-daily ATP citrate lyase inhibitor that reduces cholesterol synthesis in the liver. This unique mechanism of action is complementary to...

Ucell and P.I. Works Teamed Up to Turn Business and Network Data into Actionable Insights

ISTANBUL–(BUSINESS WIRE)– Ucell, one of the leading operators in Central Asia, and P.I. Works teamed up for implementing an integrated network and business performance management...

F-star Therapeutics Announces FDA Acceptance of IND Application for FS120

F-star’s first-in-class dual-agonist tetravalent bispecific antibody targeting CD137 and OX40 set to enter the clinic CAMBRIDGE, England & CAMBRIDGE, Mass.–(BUSINESS WIRE)– F-star Therapeutics Ltd., a...